Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Lifespan extension in animal studies Rodent studies (most extensive data): Mice lifespan increased 20-42% with Epithalon Rats showed 12-25% lifespan extension Both maximum lifespan and median lifespan increased Healthspan (healthy years) improved even more Similar to effects seen with caloric restriction but without dietary limitation Study examples: Mechanisms of lifespan extension: Telomere preservation preventing cellular senescence Reduced oxidative damage to tissues Improved immune function preventing infections Better hormone regulation (pineal, reproductive) Reduced age-related diseases (cancer, cardiovascular) Human lifespan effects (theoretical): No completed human lifespan studies (require decades) If similar extension: 20% of 80-year lifespan = 16 additional years More realistically: Healthspan improvement more achievable than lifespan Quality of life in later years potentially enhanced Similar goals as other longevity interventions Limitations of animal data: Rodents humans (metabolism, telomere biology differ) Controlled lab conditions vs real-world human life Optimal dosing in humans unknown Long-term safety in humans not established Need rigorous human trials for validation Compare to other longevity approaches like growth hormone peptides at SeekPeptides
BPC-157 has no FDA-approved dose
A recent attempt focused on the inhibition of GLSs
Side effects commonly associated with the GLP-1 drug class include nausea, vomiting, diarrhea, and GI discomfort, particularly during the titration phase
Researchers may track changes in molecular markers, such as pathway readouts or gene-expression signals, to better understand how short peptides can probe age-related cellular processes in experimental models
Stacking Protocols Stacking with other GLP-1 agonists (tirzepatide, liraglutide) is described as redundant overlapping mechanisms increase side effects without proportional benefits
